Andrew Reardon
CLO & Secretary · 6 filings · Latest: Jun 1, 2026
LIGAND PHARMACEUTICALS INC
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
LGND | ANDREW REARDON | — | Jul 1, 2026 | Proposed Sale | $316.09 | 10,000 | $3.2M | — | |
LGND | Andrew Reardon | CLO & Secretary | Jun 1, 2026 | Sale | $227.06 | 5,000 | $1.1M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | Jun 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | May 1, 2026 | Sale | $231.31 | 5,000 | $1.2M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | May 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | Apr 1, 2026 | Sale | $201.24 | 5,000 | $1.0M | 41,382 | |
LGND | Andrew Reardon | CLO & Secretary | Apr 1, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 46,382 | |
LGND | Andrew Reardon | CLO & Secretary | Mar 4, 2026 | Sale | $206.35 | 5,000 | $1.0M | 36,869 | |
LGND | Andrew Reardon | CLO & Secretary | Mar 4, 2026 | Option Exercise | $52.27 | 5,000 | $261.4K | 41,869 | |
LGND | ANDREW REARDON | — | Mar 4, 2026 | Proposed Sale | $204.24 | 20,000 | $4.1M | — | |
LGND | ANDREW THOMAS REARDON | — | Jun 23, 2025 | Proposed Sale | $114.08 | 500 | $57.0K | — | |
LGND | ANDREW THOMAS REARDON | — | Jun 10, 2025 | Proposed Sale | $114.54 | 500 | $57.3K | — | |
LGND | ANDREW THOMAS REARDON | — | May 15, 2025 | Proposed Sale | $104.00 | 1,000 | $104.0K | — | |
LGND | Reardon Andrew | — | Sep 23, 2024 | Proposed Sale | $99.60 | 2,000 | $199.2K | — | |
LGND | Reardon Andrew | — | Aug 28, 2024 | Proposed Sale | $106.39 | 1,500 | $159.6K | — |